**Description**

**A FORMULATION INTENDED TO HAVE AN ANTI-CARCINOGENIC EFFECT WITH ITS NADH OXIDASE SUPPRESSION CAPABILITY**

**Field of Invention**

The present invention herewith discloses a formulation developed to display anti-carcinogenic effect with its NADH oxidase suppression capability.

**Background of the Related Technology**

At present it is known that nicotinamide adenine dinucleotide (NAD+) is an important co-enzyme found in the cells. It plays a role in transferring reduction potential between the molecules by carrying electrons. NADH is the reduced form of NAD+ and thus NAD+ is the oxidized form of NADH.

In state of art technology, invention no “WO 1999/053921", with title “A Composition Containing L-Carnitine or an Alkanoyl L-Carnitine and NADH and/or NADPH” and under classification number “A61K 31/455 “discloses a beneficial composition that contains L-carnitine or an alkanoyl L-carnitine or their pharmaceutically acceptable salt and NADH and/or NADPH, and used as a drug in treatment of chronic fatigue syndrome and Parkinson’s disease and as a diet supplement for people undergoing exhausting physical exercises or for weak experimental subjects.

Again invention no “EP1562613B1", with title “A composition containing NADH/NADPH” and under classification number “A61K 31/70” discloses a composition that contains at least one antioxidant A that has a redox potential below 180 mV, is isolated and enhances health and at least one antioxidant B that is isolated, stabilizes antioxidant A and has a standard redox potential that is below the standard redox potential of antioxidant A. The referred invention also discloses the methods of using this composition and the methods for manufacturing it.

–

Again invention no “EP2043659B1", with title “An Anti-Carcinogenic Treatment that Includes H2-blocker, at least One Anti-Inflammatory Agent and a Cytotoxic Agent” and under classification number “A61K 31/675 “discloses a pharmaceutical composition that consists of the following substances and also is related to treatment of a mammal: H2-blocker, at least one anti-inflammatory agent, a cytotoxic agent and optionally levamisole, retinoid, NFkB inhibitor, redox quinone, an agent increasing intracellular accumulation of NADH + H+, poly-alcohol, pro-angiogenic growth factor inhibitor and MMP inhibitor. Such a pharmaceutical composition allows improved treatment and/or prevention of neoplastic diseases and disorders.

To conclude it has become inevitable to proceed with a development in the area of the related technology, considering the inadequacy of the existing solutions and the need for a formulation intended to display anti-carcinogenic effect with its NADH oxidase suppression capability.

**Objective of the Invention**

To overcome the disadvantages experienced in state of art technology;

* One objective of the invention is to suppress NADH oxidase expression.
* One other objective of the invention is for it to display FMO3 suppressing capability.
* One other objective of the invention is for it to display cox-2 suppressing capability.

The present invention which is aimed to achieve the above-mentioned advantages, is intended to display anti-carcinogenic effect with its NADH oxidase suppression capability and is a formulation that is obtained by combination of the compositions selected in a single form or in combinations from a group containing; 3,5-bis(3-methoxyethyl)-6-0-(3-methyl-2-butene-1-yl)-4H-1-benzopyrane-4-one, 1-[2-trihydroxy-4-methoxy-3-(3-ethylbut-2-ene-1-yl)diphenyl]-3-hexaphenylprop-2-ene-1-triol.

Structural and characteristic properties as well as all the advantages of the invention presented herewith will be clearly understood with the detailed description provided below and thus the evaluation regarding the present invention should be based on the detailed description presented herewith.

**Detailed Description of the Invention**

The present invention herewith discloses a formulation intended to display anti-carcinogenic effect with its NADH oxidase suppression capability. Referred formulation suppresses NADH oxidase expression, displays FMO3 suppressing capability, displays cox-2 suppressing capability.

The formulation of the invention presented herewith contains; 3,5-bis(3-methoxyethyl)-6-0-(3-methyl-2-butene-1-yl)-4H-1-benzopyrane-4-one, 1-[2-trihydroxy-4-methoxy-3-(3-ethylbut-2-ene-1-yl)diphenyl]-3-hexaphenylprop-2-ene-1-triol .

The referred formulation is formed by mixing the above-mentioned components at below percentages by weight;

* 1-99% of 3,5-bis(3-methoxyethyl)-6-0-(3-methyl-2-butene-1-yl)-4H-1-benzopyrane-4-one,
* 99-1% of 1-[2-trihydroxy-4-methoxy-3-(3-ethylbut-2-ene-1-yl)diphenyl]-3-hexaphenylprop-2-ene-1-triol.

Components given above are obtained by combining the components from the above-mentioned group at the given range of weight ratios in a single form or in combinations thereof.

The present invention at the same time discloses using the above-referred formulation to display anti-carcinogenic effect with its NADH oxidase suppression capability and manufacturing it for such purpose.

**CLAIMS**

1. A formulation intended to display anti-carcinogenic effect with its NADH oxidase suppression capability, which consists of combining the components selected from the group; 3,5-bis(3-methoxyethyl)-6-0-(3-methyl-2-butene-1-yl)-4H-1-benzopyrane-4-one, 1-[2-trihydroxy-4-methoxy-3-(3-ethylbut-2-ene-1-yl)diphenyl]-3-hexaphenylprop-2-ene-1-triol in a single form or in combinations thereof
2. The formulation of Claim 1 which is characterized by containing 1-99% of 3,5-bis(3-methoxyethyl)-6-0-(3-methyl-2-butene-1-yl)-4H-1-benzopyrane-4-one by weight.
3. The formulation of Claim 1 which is characterized by containing 99-1% of 1-[2-trihydroxy-4-methoxy-3-(3-ethylbut-2-ene-1-yl)diphenyl]-3-hexaphenylprop-2-ene-1-triol by weight.
4. Using the compositions obtained by selecting singly or in combination of components from the group of; 3,5-bis(3-methoxyethyl)-6-0-(3-methyl-2-butene-1-yl)-4H-1-benzopyrane-4-one, 1-[2-trihydroxy-4-methoxy-3-(3-ethylbut-2-ene-1-yl)diphenyl]-3-hexaphenylprop-2-ene-1-triol from any one as given in Claims 2-3 in manufacturing the formulation intended to display anti-carcinogenic effect with its NADH oxidase suppression capability.

**SUMMARY**

**A FORMULATION INTENDED TO HAVE AN ANTI-CARCINOGENIC EFFECT WITH ITS NADH OXIDASE SUPPRESSION CAPABILITY**

The present invention herewith discloses a formulation intended to display anti-carcinogenic effect with its NADH oxidase suppression capability. Referred formulation suppresses NADH oxidase expression, displays FMO3 suppressing capability, displays cox-2 suppressing capability

There are no illustrations.